CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Nutrasorb bardietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05130593
NCT05130593N/ACompleted
CompareCT.gov

Pilot Study Evaluating the Hedonic Acceptability and Absorption of the Bioactive Compounds of a 5011-Nutrasorb Bar (Russian Tarragon Nutrasorb)

Pennington Biomedical Research Center·observational·Posted Nov 23, 2021·Updated Nov 18, 2023

In Brief

An observational study evaluating Nutrasorb bar for Diabetes Prevention. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to make a bar from the soy-protein Russian Tarragon complex (PMI-5011/Nutrasorb) that is safe and acceptable for consumption, and to test the blood levels of plasma bioactive (DMC-2) after ingestion of the bar. The PMI-5011/Nutrasorb comes from a plant source called Artemisia dracunculus. This plant has a long history of medicinal (health) and culinary (food) use and has been reported as effective as a traditional treatment for diabetes in various parts of the world.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Prevention
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 23, 2021
Enrollment StartOct 25, 2021
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.6 years ago

Interventions

Nutrasorb bardietary

250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings